

Test GBM Analytics Report

Generated on: September 24, 2025 at 12:04 AM

Executive Summary

| Metric | Value |
|------------------------------|-------|
| Total Patients | 43 |
| Patients with Survival Data | 38 |
| Mean Overall Survival (days) | 723.2 |
| Progression Rate | 55.8% |
| Overall Response Rate | 0.0% |

Survival Analysis

| Survival Metric | Mean (days) | Median (days) | Sample Size |
|---------------------------|-------------|---------------|-------------|
| Overall Survival | 723.2 | 702.5 | 38 |
| Time to Progression | 566.2 | 543.5 | 24 |
| Progression-Free Survival | 625.3 | 602.0 | 38 |

Key Findings:

- 43 of 43 patients are alive
- 24 patients have experienced progression
- Progression rate: 55.8%

Treatment Response Analysis


No treatment response data available.

Molecular Marker Correlations

| Biomarker | Category | Count | Percentage |
|------------|----------|-------|------------|
| IDH Status | Wildtype | 33 | 78.6% |
| IDH Status | Unknown | 3 | 7.1% |
| IDH Status | Mutant | 6 | 14.3% |

| | | | |
|-------------|--------------|----|-------|
| MGMT Status | Unmethylated | 20 | 47.6% |
| MGMT Status | Methylated | 19 | 45.2% |
| MGMT Status | Unknown | 3 | 7.1% |

Statistical Visualizations



Methodology and Notes

Data Analysis Methodology:

- Survival metrics calculated from diagnosis date to last follow-up or event
- Time-to-progression defined as time from diagnosis to first progressive disease
- Treatment response assessed using RECIST criteria when available
- Molecular markers analyzed for correlation with clinical outcomes
- Statistical calculations performed using standard clinical research methods

Limitations:

- Analysis based on available data; missing data may affect results
- Follow-up times may vary between patients
- Treatment response assessment dependent on imaging availability

Generated by: GBM Tracker Advanced Analytics Engine

Report Date: September 24, 2025